Book a Meeting

Development of Phage Lysin-antibiotic Combined Therapy

Recently, Phage lysin-antibiotic combination therapy has broad prospects. Based on the advanced lysin research platform, Creative Biolabs focuses on providing phage lysin-antibiotic combined therapy development services to meet the different purposes of our clients, expanding the scope of applicable targets. Our highly skilled scientists are ready to begin your project.


In recent years, the global epidemic of antibiotic resistance has posed a significant threat to public health. The emergence of bacteriophage lysins offers a promising solution to growing antibiotic resistance. Lysins are a class of enzymes produced by bacteriophages that cleave key bonds in the bacterial cell wall causing rapid death of bacteria. There are many successful cases of lysins alone as antimicrobials, but there are also many cases where lysins are used in combination with another class of antimicrobials to obtain synergistic effects against infection.

Vital Roles of Combination of Lysins and Antibiotics

Evidence shows synergistic effects of lysins and traditional antibiotics against various bacteria such as Staphylococcus aureus. In vivo experiments indicated that in the methicillin-resistant S. aureus (MRSA) sepsis model, chimeric lysins can markedly improve survival when combined with specific antibiotics. Furthermore, the superiority of lysin CF-301 in combination with antibiotics was demonstrated in 26 independent bacteremia studies. The correct combination of lysins and antibiotics will be beneficial to controlling drug-resistant bacteria and restoring the application of some antibiotics that have developed resistance, which may bring new hope to traditional antibiotics. In conclusion, there is increasing evidence revealing that the combination of lysins and antibiotics is a valid alternative to antibiotic monotherapy currently used for the treatment of multiple bacterial infections.

In vitro and in vivo activities of CF-301.Fig.1 In vitro and in vivo activities of CF-301. (Schuch, 2014)

Potential Synergistic Reaction Mechanisms

Lysins can enhance antibiotic activity by interacting with the cell wall to facilitate antibiotic uptake. Therefore, the correct combination of lysins and antibiotics not only contributes to the treatment of drug-resistant bacteria but also facilitates the resensitization of bacteria to antibiotic-resistant antibiotics. Combining lysins with antibiotics is beneficial in reducing the emergence of lysins or antibiotic-resistant mutants. Additionally, this approach enables antibiotics to be administered at lower doses.

What Can We Do?

  • In Vitro Services

At Creative Biolabs, several different methods are available to determine lysin synergy in vitro, such as time-kill assays and isobolograms. Using different strategies, our scientists observed clear synergistic effects between lysins and various antibiotics. With extensive experience and a well-established design protocol, we have successfully identified multiple combinations of lysins with different cleavage specificities that are synergistic and highly lethal to specific bacteria.

  • In Vivo Services

In addition to in vitro assays, diverse animal models are also available at Creative Biolabs. We focused on exploring the in vivo synergy between lysin and beta antibiotics. We have completed numerous projects showing that lysins can significantly improve in vivo efficacy when combined with specific antibiotics. Our services include but not limit to:

For your convenience, we provide one-stop phage lysin-antibiotic combination therapy development services, covering experimental design, project implementation, and results analysis. What's more, we also welcome specific requests from customers. If you are interested in our services, please contact us for more details.


  1. Schuch, R.; et al. Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus–induced murine bacteremia. The Journal of infectious diseases. 2014, 209(9): 1469-1478.
For Research Use Only. Do NOT use in humans.

Send Inquiry

* For Research Use Only. We do not provide direct services or products for patients.